All payments made in the preview are in test mode. Read more
Sign in
Back to Atlas
CTransientStandard research/education caution
CMP-0459
Approved

Tamoxifen

Endocrine / SERM

ER-positive breast cancer treatment/prevention and endocrine modulation

Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type
SERM
Primary mechanism
Estrogen receptor modulation; ER antagonist in breast tissue
Primary market use
Oncology / endocrine

Pharmacology

Molecular weight (Da)
371.5 base; 563.6 citrate
Oral bioavailability
Oral; high
Half-life
~5-7 d; active metabolites longer
Route tags
Route-dependent / verify
Evidence level
Approved
Clinical status
Approved
Value-for-money score
5 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Durable disease outcomes possible, but pharmacologic ER modulation requires ongoing dosing

Sources

Educational and organizational assistant matrix. Not medical advice.

BioChrysalis Atlas is an educational, organizational, and tracking asset. It does not provide medical advice, diagnosis, treatment, prescriptions, or individualized dosing instructions. Compound profiles, protocol notes, and dosage fields summarize publicly discussed or source-listed reference patterns and are not recommendations. Consult a qualified healthcare professional before starting, stopping, or modifying any compound, medication, or supplement protocol.

© BioChrysalis · Evolve · Ascend · Transcend